⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
NVO News
Novo-Nordisk A/S
FDA approves Novo Nordisk's Sogroya® as the first and only once-weekly, long-acting growth hormone for three additional pediatric indications
prnewswire.com
NVO
Bronstein, Gewirtz & Grossman, LLC Encourages Novo Nordisk A/S (NVO) Investors to Inquire about Securities Investigation
accessnewswire.com
NVO
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Novo Nordisk A/S - NVO
accessnewswire.com
NVO
SkinnyRx GLP-1 Weight Loss 2026: Compounded Semaglutide and Tirzepatide Program, Pricing, and FDA Regulatory Status Examined
globenewswire.com
ELAN
LLY
NVO
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Novo Nordisk A/S - NVO
prnewswire.com
NVO
PatentVest Releases New Report on The Oral Small-Molecule GLP-1 Patent Race
globenewswire.com
MDBH
LLY
NVO
PFE
AZN
GILD
GPCR
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Novo Nordisk A/S (NVO) And Encourages Investors to Reach Out
accessnewswire.com
NVO
Walgreens Virtual Healthcare Adds Weight Management Services to Support Patients on Their Weight Loss Journey
businesswire.com
NVO
Commitments Received for ~A$8.2m Placement
globenewswire.com
NVO
New Study Shows Scripps Patients Maintained Weight Loss After Reducing GLP-1 Treatment Frequency
globenewswire.com
LLY
NVO